Fractyl GLP-1 obesity gene therapy outdoes semaglutide for weight loss in mice

Fractyl Health’s GLP-1-based pancreatic gene therapy has outperformed semaglutide injections for weight loss at least in mice.

In a presentation Oct. 4 at the annual conference of the European Association for the Study of Diabetes, or EASD, the company presented data showing that a single dose of its GLP-1 PGTx, known by the trade name Rejuva, was able to reduce body fat by about 25% in a mouse model of Type 2 diabetes, compared to roughly 18% in animals that were given daily doses of semaglutide.

Semaglutide is marketed by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss. The drug has sparked a gold rush in the obesity market with companies trying to improve on the market leader. Fractyl is behind bigger names like Pfizer and Eli Lilly, which has received a diabetes approval for its Mounjaro. Novo, meanwhile, has been stacking its pipeline with next-gen options.  

“We aim to design a better GLP-1 therapy which has the potential for more potency, better tolerability, and more durability,” Fractyl Chief Scientific Officer Timothy Kieffer, Ph.D., said in a press release. “[Rejuva] has the potential to offer these benefits because it targets the pancreas, is designed to mimic human physiology, and may provide durable benefits that persist after the treatment itself.”

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!